# Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months

> **NCT03671616** · PHASE3 · COMPLETED · sponsor: **Statens Serum Institut** · enrollment: 666 (actual)

## Conditions studied

- Poliomyelitis

## Interventions

- **BIOLOGICAL:** IPV-Al SSI

## Key facts

- **NCT ID:** NCT03671616
- **Lead sponsor:** Statens Serum Institut
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-15
- **Primary completion:** 2018-10-03
- **Final completion:** 2018-10-03
- **Target enrollment:** 666 (ACTUAL)
- **Last updated:** 2018-11-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03671616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03671616, "Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03671616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*